E
Exscientia
Applying artificial intelligence and big data processing to accelerate discovery and development of drugs
Latest news
Press, funding announcements and product moves mentioning Exscientia.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later17 investors entered at this stage
BlackRock- LMLaurion Capital Management
- CECelgene
- NSNovo Seeds
- BSBristol-Myers Squibb
Mubadala Capital
Casdin Capital
SoftBank- NHNovo Holdings
- FGFrontier IP Group
- UDUniversity of Dundee
SoftBank Vision Fund- MWMarshall Wace
- FMFarallon Capital Management
- PSPivotal Life Sciences
- GTGT Technologies
- GHGT Healthcare
Source: Dealroom Talent Intelligence.
Alumni founders
Former Exscientia employees who went on to found companies, sorted by Dealroom signal score.
MBMyricx BioEst. 2019
Andrew BellUnited Kingdom
Gregory VladimerAustria
CTCHARM TherapeuticsEst. 2021
Laksh AithaniUnited Kingdom
ATAffinia TherapeuticsEst. 2019
Rob Johnson.United StatesGlobal footprint
team presence
across markets
Patents
16 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exscientia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exscientia on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.